Treatment Guides

Managing GVHD treatment side effects: symptoms, monitoring, and continuity of care

During graft-versus-host disease treatment, fatigue, diarrhea, or an abnormal liver test may have several possible explanations. GVHD itself, infection, medication effects, and other transplant complications can overlap. A symptom appearing after a prescription change is worth reporting, but timing alone does not prove which medicine caused it. Stopping everything to see what happens can make the underlying disease harder to control.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

  • After allogeneic transplantation, a temperature of 38°C or higher warrants immediate contact with the transplant team and assessment according to its instructions. Chills, breathlessness, chest discomfort, and redness or drainage around a central line also deserve prompt attention. Severe breathing difficulty, altered consciousness, substantial bleeding, or collapse requires local emergency care rather than waiting for an overseas reply. Immunosuppression can make infection less obvious; the absence of a high fever does not establish safety.[1]
  • Ibrutinib has a defined US chronic GVHD indication, and its labeling describes risks including hemorrhage, serious infection, arrhythmias, and hypertension. When it is being considered or used, the team should know about anticoagulants, antiplatelet medicines, and potential interactions. Persistent palpitations, chest pain, black stools, or significant bleeding should not wait for a routine appointment.[7]
  • Before leaving a Chinese treatment center, obtain a dated medicine list, recent blood counts and organ-function results, the tests required next, and the clinician responsible for acting on abnormalities. Include generic names, formulation, strength, and administration times. This reduces confusion when brands differ or a similarly named product is supplied in another country.

Quick answer

During graft-versus-host disease treatment, fatigue, diarrhea, or an abnormal liver test may have several possible explanations. GVHD itself, infection, medication effects, and other transplant complications can overlap. A symptom appearing after a prescription change is worth reporting, but timing alone does not prove which medicine caused it. Stopping everything to see what happens can make the underlying disease harder to control.

Full guide

During graft-versus-host disease treatment, fatigue, diarrhea, or an abnormal liver test may have several possible explanations. GVHD itself, infection, medication effects, and other transplant complications can overlap. A symptom appearing after a prescription change is worth reporting, but timing alone does not prove which medicine caused it. Stopping everything to see what happens can make the underlying disease harder to control.

The aim of side-effect management is to preserve both disease control and daily function. Depending on the cause and severity of a problem, the team may adjust a dose, change treatment, interrupt a medicine, or add supportive care. This article explains the observations that help that decision and the monitoring arrangements needed when treatment takes place in China and follow-up continues elsewhere. Sources were checked in September 2026.

Recognize symptoms that need immediate contact

After allogeneic transplantation, a temperature of 38°C or higher warrants immediate contact with the transplant team and assessment according to its instructions. Chills, breathlessness, chest discomfort, and redness or drainage around a central line also deserve prompt attention. Severe breathing difficulty, altered consciousness, substantial bleeding, or collapse requires local emergency care rather than waiting for an overseas reply. Immunosuppression can make infection less obvious; the absence of a high fever does not establish safety.[1]

Tell emergency clinicians that the patient has received an allogeneic stem cell transplant and is being treated for GVHD. Bring the medicine list and allergy history. Report the highest temperature, when it began, accompanying symptoms, and the date of the most recent treatment. Fever following an infusion should not automatically be dismissed as an expected reaction, and lowering the temperature does not establish that the cause has been addressed.

Reconstruct what changed before trying to name the cause

Worsening diarrhea may reflect intestinal GVHD, an infection, or medication effects. Jaundice or elevated liver enzymes likewise require clinical interpretation. Acute GVHD assessment includes considering conditions that resemble it; stool testing, viral investigations, or tissue sampling may be appropriate depending on the presentation. The transplant team decides which investigations will change management.[2]

A short daily record can be more useful than a long account recalled at the next visit. Note temperature, bowel changes, oral intake, rash distribution, and weight trends, together with medicines recently started, stopped, or reduced. Include drops, creams, supplements, and herbal products. This is a way to give clinicians usable evidence, not a request for patients to assign themselves a toxicity grade. A deteriorating condition should be reported before a planned diary period is complete.

Discuss corticosteroid effects early and avoid abrupt withdrawal

Corticosteroids can affect glucose, sleep, mood, weight, and muscle strength; longer exposure also raises bone and eye concerns. Persistent thirst, frequent urination, pronounced sleep disruption, or an unusual mood change should be discussed even when no scheduled blood test has yet shown a problem. Monitoring depends on the dose, duration, and individual risks.[3]

These medicines also suppress the body's own steroid response. Abrupt discontinuation after prolonged treatment can be dangerous, and infection, injury, or surgery may require special management. Improvement in a rash is therefore not permission to stop treatment independently. A taper should specify the dose at each stage, review arrangements, and whom to contact if vomiting prevents oral medication. Another patient's successful taper is not a reliable substitute for an individual plan.

Interpret falling blood counts by component and trend

Ruxolitinib treatment can be associated with anemia, thrombocytopenia, and neutropenia. These are not interchangeable findings: they raise different questions about fatigue or breathlessness, bleeding, and susceptibility to infection. Clinicians also consider other medicines, infection, marrow recovery, and the original disease. Not every low count after transplantation is caused by the GVHD drug.[4]

The 2026 US ruxolitinib information includes different formulations. Dosing and monitoring must correspond to the actual product and indication; a table for another formulation should not be used to convert a Chinese prescription. Bring consecutive results rather than only the most recent abnormal value. The speed of change and the rest of the clinical picture help determine whether treatment can continue, requires modification, or needs further investigation. An online numerical threshold is not a personal instruction to omit the next dose.

Some important abnormalities appear before symptoms

The Chinese prescribing information for belumosudil requires liver monitoring and attention to interacting medicines, including certain acid-suppressing drugs and strong enzyme inducers. A new liver abnormality may have more than one cause, and the response depends on its severity. Even a medicine described as “stomach protection” can alter another treatment's exposure, so new prescriptions should be included in medication review.[5]

For patients receiving axatilimab, the current US label calls for tests including liver enzymes, creatine phosphokinase, amylase, and lipase. The significance of an elevated result needs clinical interpretation; different laboratory changes do not necessarily represent the same tissue injury. Feeling well is not a reason to skip required monitoring. These US product requirements describe care for that treatment and do not establish its availability in a Chinese hospital.[6]

Bleeding, palpitations, and blood pressure require a combination review

Ibrutinib has a defined US chronic GVHD indication, and its labeling describes risks including hemorrhage, serious infection, arrhythmias, and hypertension. When it is being considered or used, the team should know about anticoagulants, antiplatelet medicines, and potential interactions. Persistent palpitations, chest pain, black stools, or significant bleeding should not wait for a routine appointment.[7]

Dental work, endoscopy, and other procedures should be discussed with both the procedural clinician and the transplant team in advance. Any interruption depends on bleeding risk and the need to maintain disease control. Independently stopping anticoagulation or immunosuppression can create a different hazard. A warning in prescribing information should prompt a clinical discussion rather than become a self-written stopping schedule.

Local treatment still needs specialist oversight

Steroid eye drops can help selected inflammatory problems, but prolonged or inappropriate use can affect eye pressure and contribute to cataract or infection risk. Eye pain, light sensitivity, or a change in vision needs examination to distinguish GVHD from infection, corneal injury, or another cause. Increasing drops or relying only on artificial tears cannot make that distinction.[8]

Oral GVHD can also coexist with fungal infection, damaged mucosa, and painful lesions during local immune treatment. Oral examination, prescribed care, and changes that support eating may all be needed. Persistent ulcers, an inability to eat, or a new localized lesion should be reported. Calling every white patch or sore area “the usual GVHD” can delay assessment of a different problem.[9]

Infusions and photopheresis involve additional practical risks

During an infusion, tell the nurse immediately about a rash, chills, breathlessness, or a sudden change in how the patient feels. Axatilimab labeling contains specific instructions for managing infusion reactions; slowing, interrupting, or discontinuing treatment is a clinical decision based on severity.[6] Cellular products also have product-specific administration and monitoring requirements. A treatment containing cells should not be assumed to be free of adverse effects.[10]

Extracorporeal photopheresis involves vascular access, anticoagulation, and a photosensitizing medicine. Access problems, blood pressure changes, and other procedure-related symptoms require attention. Follow the center's instructions for protecting eyes and skin after treatment. A patient with heart or kidney disease should not copy a standard fluid intake recommendation from an unrelated patient leaflet; the day's medication, food, and fluid instructions need to fit the individual.[11]

Infection prevention is a planned part of treatment

Antiviral, antifungal, and Pneumocystis prevention may remain necessary while a patient feels well. Their use depends on the immune-suppression pattern and individual risk. Conversely, a new fever should not be managed only by taking leftover antibiotics. Long-term transplant recommendations emphasize adherence to prescribed prevention and a revaccination program, with the actual products and timing adapted to immune recovery and national guidance.[12]

When prescriptions are rewritten at a new hospital or after returning home, preventive medicines can be overlooked. Ask for each medicine's purpose and stopping criteria to be recorded. Distinguishing treatment for GVHD from infection prevention and symptom control helps the receiving clinician understand the plan. It is not a reason for the patient to remove a medicine because it appears unrelated to the main diagnosis.

Include nutrition, strength, and emotional effects in review

Weight gain does not always show nutritional recovery; fluid retention or corticosteroid effects may contribute. Weight loss may reflect reduced intake, malabsorption, or greater illness-related needs. Nutrition review considers eating ability, gastrointestinal function, and muscle performance. Supplements alone cannot resolve every cause. Oral or enteral support has a role when the gut can be used, while parenteral nutrition is reserved for appropriate situations rather than treated as a universally stronger option.[13]

Fatigue, poor sleep, and caregiver strain can disrupt medication routines and appointments. Children may face additional difficulties with school, activity, and development. Reporting these concerns allows rehabilitation, psychological, and social support to be considered. Patient-centered GVHD work emphasizes functioning and treatment burden as meaningful outcomes; the point is to improve the care plan, not to explain physical illness away as an emotional problem.[14]

Make the cross-border monitoring plan executable

Before leaving a Chinese treatment center, obtain a dated medicine list, recent blood counts and organ-function results, the tests required next, and the clinician responsible for acting on abnormalities. Include generic names, formulation, strength, and administration times. This reduces confusion when brands differ or a similarly named product is supplied in another country.

Confirm that the home laboratory can perform essential tests and that the report format and units can be interpreted by the receiving team. Decide where results will be sent and how urgent findings will be handled. If a scheduled test cannot be completed, the patient needs a contact route rather than having to decide alone whether a medicine should continue.

Monitoring, specialist visits, infection treatment, and possible readmission also affect cost. A reliable total requires an individual prescription and a verifiable RMB quotation for care in China. The most useful side-effect plan identifies who prescribes, who reviews results, what requires emergency care, and what should bring the next appointment forward. Patients do not need to diagnose the exact adverse reaction before asking for help.

References

  1. MSK. Leaving hospital after an allogeneic transplant: https://www.mskcc.org/cancer-care/patient-education/leaving-hospital-after-your-allogeneic-transplant
  2. EBMT Handbook. Acute GVHD: https://www.ncbi.nlm.nih.gov/books/NBK608233/
  3. MSK. Prednisone patient information: https://www.mskcc.org/cancer-care/patient-education/medications/adult/prednisone
  4. FDA. Ruxolitinib prescribing information, 2026: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217180s001lbl.pdf
  5. Sanofi China. Belumosudil prescribing information, January 2026 revision: https://www.sanofi.cn/assets/dot-cn/pages/docs/products/prescription-products/rezurock-cn-20260122.pdf
  6. DailyMed. Current US axatilimab prescribing information: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bb6dba23-e7a6-4765-a1e6-b9e277ce0381&type=display
  7. DailyMed. US ibrutinib prescribing information: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44
  8. EBMT Handbook. Ocular and oral complications: https://www.ncbi.nlm.nih.gov/books/NBK608294/
  9. NIH. Ancillary therapy and supportive care in chronic GVHD: https://pmc.ncbi.nlm.nih.gov/articles/PMC4821166/
  10. FDA. Ryoncil product and prescribing-information page: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/ryoncil
  11. MSK. Photopheresis patient information: https://www.mskcc.org/cancer-care/patient-education/frequently-asked-questions-about-photopheresis
  12. International recommendations for long-term transplant screening and prevention, 2023 update published in 2024: https://pmc.ncbi.nlm.nih.gov/articles/PMC11181337/
  13. EBMT Handbook. Nutritional support: https://www.ncbi.nlm.nih.gov/books/NBK608249/
  14. PTCTC RESILIENT. Patient-important outcomes in pediatric chronic GVHD: https://pmc.ncbi.nlm.nih.gov/articles/PMC11957933/

Related guides